Efficacy, Tolerability, and Safety of DFN-15

Migraine Headache Clinical Trial

Official title:

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy, Tolerability, and Safety Study of DFN-15 in Episodic Migraine With or Without Aura

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03009019
• Other study ID #: DFN-15-CD-006
• Status: Completed
• Phase: Phase 3
• Start date: December 2016
• Est. completion date: May 2019

Study information

• Verified date: December 2022
• Source: BioDelivery Sciences International
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Efficacy, Tolerability, and Safety of DFN-15 in episodic migraine with or without aura, being conducted at multiple centers in the United States

Recruitment information / eligibility

• Status: Completed
• Enrollment: 631
• Est. completion date: May 2019
• Est. primary completion date: November 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. A history of episodic migraine, who experience 2 to 8 migraine attacks per month for at least the past 12 months, with no more than 14 headache days per month, and with 48 hours of headache-free time between migraine attacks.

2. Patients who have migraine with or without aura with onset before age 50 years

3. Report usual migraine pain of 2 (moderate) or 3 (severe) on headache pain severity scale without treatment.

4. Subjects who are willing and able to:

1. Evaluate and record pain, migraine symptoms, and study drug effectiveness information in real-time using a subject eDiary for the duration of the study;

2. Record each instance of the use of study drug and rescue medication in real-time using a subject eDiary for the duration of the study;

3. Comply with all other study procedures and scheduling requirements.

Exclusion Criteria:

1. Minors, even if they are in the specified study age range

2. Medication overuse:

1. Opioids greater than or equal to 10 days during the 90 days prior to screening

2. Combination medications (e.g., Fiorinal®) greater than or equal to 10 days during the 90 days prior to screening (applies only if includes opioid and/or barbiturate)

3. Nonsteroidal Anti-inflammatory Drugs or other simple medications greater than 14 days a month during the 90 days prior to screening

4. Triptans or ergots greater than or equal to 10 days a month during the 90 days prior to screening

3. Treated with onabotulinumtoxin A (Botox®) for migraine within 4 months prior to screening. (If treated for cosmetic reasons, subjects may be included).

4. Current treatment with antipsychotics or use of antipsychotics within 30 days prior to randomization.

5. Patients who have received treatment with an investigational drug or device within 30 days of randomization, or participated in a central nervous system clinical trial within 2 months prior to randomization

6. Patients with positive screening test for human immunodeficiency virus [HIV], positive hepatitis B surface antigen (HBsAg), or positive hepatitis C virus [HCV] antibody

7. Subjects who are employees or immediate relatives of the employees of the Sponsor, any of its affiliates or partners, or of the clinical research study site.

Related Conditions & MeSH terms

• Headache
• Migraine Disorders
• Migraine Headache

Intervention

Drug:
• DFN-15 Active

Other:
• DFN-15 Placebo

Locations

Country	Name	City	State
United States	Site 636	Albuquerque	New Mexico
United States	Site 634	Ann Arbor	Michigan
United States	Site 627	Austin	Texas
United States	Site 609	Birmingham	Alabama
United States	Site 604	Blue Island	Illinois
United States	Site 645	Brooklyn	New York
United States	Site 628	Cleveland	Ohio
United States	Site 612	Dakota Dunes	South Dakota
United States	Site 611	Dallas	Texas
United States	Site 625	Decatur	Georgia
United States	Site 623	Edina	Minnesota
United States	Site 626	Fargo	North Dakota
United States	Site 620	High Point	North Carolina
United States	Site 616	Hot Springs	Arkansas
United States	Site 637	Huntington Beach	California
United States	Site 647	Lebanon	New Hampshire
United States	Site 631	Littleton	Colorado
United States	Site 602	Louisville	Kentucky
United States	Site 642	Meridian	Idaho
United States	Site 603	Miami	Florida
United States	Site 606	Missoula	Montana
United States	Site 640	Mobile	Alabama
United States	Site 643	Mooresville	North Carolina
United States	Site 639	Mount Pleasant	South Carolina
United States	Site 618	Nashua	New Hampshire
United States	Site 610	New Orleans	Louisiana
United States	Site 644	New Orleans	Louisiana
United States	Site 615	Oakland	California
United States	Site 613	Omaha	Nebraska
United States	Site 641	Orange City	Florida
United States	Site 629	Orlando	Florida
United States	Site 635	Richmond	Virginia
United States	Site 608	Rochester	New York
United States	Site 638	Saint Peters	Missouri
United States	Site 632	San Antonio	Texas
United States	Site 646	San Diego	California
United States	Site 619	San Francisco	California
United States	Site 624	San Marcos	California
United States	Site 630	Sandy Springs	Georgia
United States	Site 621	Taylorsville	Utah
United States	Site 622	Tucson	Arizona
United States	Site 614	Warwick	Rhode Island
United States	Site 601	West Palm Beach	Florida

Sponsors (2)

Lead Sponsor	Collaborator
BioDelivery Sciences International	Dr. Reddy's Laboratories Limited

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of Subjects Who Are Pain-free at 2 Hours Postdose (First Treated Double-blind Treatment Period)	The primary efficacy end point (for first treated DB1 attack only) were the percentage of subjects who were pain-free 2 hours postdose compared between DFN-15 and placebo (defined as a reduction from predose moderate [Grade 2] or severe [Grade 3] pain to none [Grade 0]	2 hours postdose
Primary	Percentage of Subjects Who Are Free From Their MBS at 2 Hours Postdose	Percentage of subjects who are free from their Most Bothersome Symptom (MBS) among nausea, photophobia, and phonophobia (first double-blind treatment period)	2 hours postdose
Secondary	The Number of Subjects With TEAEs After Study Drug Compared Between DFN-15 and Placebo	For DB1: TEAE that started or worsening of a pre-existing condition on or after the first dose of study drug (DFN-15 or placebo) in to taking DB2 study drug, whichever occurs first.; For DB2: TEAE that started or worsened on or after the first dose of study drug in DB2 up to 5 days after the date of the last dose of study drug in DB2.	Per protocol, the maximum dosing timeframe for DB2 was 10 weeks; therefore, the maximum AE collection window was 11 weeks total.
Secondary	Freedom From Nausea, Photophobia, and Phonophobia Postdose (DB1 and DB2)	The percentage of subjects who were free from nausea, photophobia, and phonophobia at 15, 30, and 45 minutes and 1, 1.5, 2, 4, and 24 hours postdose compared between DFN-15 and placebo	15 minutes to 24 hours postdose
Secondary	Time to Headache Pain Relief Postdose (DB1 and DB2)	The time to headache pain relief was defined as the time in minutes from when a subject took study drug until the time pain relief was indicated by the subject in the eDiary within 2 hours postdose.	2 hours postdose
Secondary	Time to Headache Pain Freedom Postdose (DB1 and DB2)	The time to headache pain freedom was defined as the time in minutes from when a subject took study drug until the time pain freedom was indicated by the subject in the eDiary within 2 hours postdose.	2 hours postdose
Secondary	Headache Pain Relief Postdose (DB1 and DB2)	Headache pain relief was defined for DB1 as a reduction from moderate or severe pain before dosing to mild or none postdose, and for DB2 as moderate or severe pain before dosing reduced to mild or none postdose, or mild pain before dosing reduced to none postdose. Data are reported by percentage reporting headache pain relief over time postdose.	15 minutes to 24 hours postdose
Secondary	Headache Pain Freedom Postdose (DB1 and DB2)	The percentage of subjects who were pain-free at 15, 30, and 45 minutes and 1, 1.5, 2 (DB2 period), 4, and 24 hours postdose compared between DFN-15 and placebo	15 minutes to 24 hours postdose
Secondary	Absence of Screening MBS at Time Points Postdose (DB1 and DB2)	The percentage of subjects with their Screening MBS (Most Bothersome Symptom) absent at 15, 30, and 45 minutes and 1, 1.5, 2 (DB2 period), 4, and 24 hours postdose compared between DFN-15 and placebo.	15 minutes to 24 hours postdose
Secondary	Change in Functional Disability Score Postdose (DB1 and DB2)	Change in functional disability score at 2, 4, and 24 hours postdose compared between DFN-15 and placebo. The values of the functional disability scale were: 0=no disability, able to function normally; 1=performance of daily activities mildly impaired, can still do everything but with difficulty; 2=performance of daily activities moderately impaired, unable to do some things; 3=performance of daily activities severely impaired, cannot do all or most things, bed rest may be necessary.; A decrease in values indicates improvement from baseline.	2 to 24 hours postdose
Secondary	Headache Pain Freedom Among Subjects With Cutaneous Allodynia (DB1 and DB2)	The percentage of subjects who were pain-free at 2 and 4 hours postdose compared between DFN-15 and placebo, among those reporting cutaneous allodynia predose	2 and 4 hours postdose
Secondary	Headache Pain Freedom Among BMI Category (DB1 and DB2)	The percentage of subjects who were pain-free at 2 and 4 hours postdose whose BMI was < 30 kg/m2 vs. subjects whose BMI was = 30 kg/m2, and whose BMI was < 25 kg/m2 vs. subjects whose BMI was = 25 kg/m2	2 and 4 hours postdose
Secondary	Headache Pain Recurrence Postdose (DB1 and DB2)	The percentage of subjects who had pain recurrence between 2 to 24 hours (i.e., pain-free at 2 hours postdose, with pain [mild, moderate, or severe] reported at 24 hours postdose) compared between DFN-15 and placebo	2 to 24 hours postdose
Secondary	Sustained Headache Pain Relief Postdose (DB1 and DB2)	The percentage of the population of subjects who reported headache pain relief between 2 and 24 hours postdose.	2 to 24 hours postdose
Secondary	Sustained Headache Pain Freedom Postdose (DB1 and DB2)	The percentage of subjects who had sustained pain freedom at 2 to 24 hours postdose compared between DFN-15 and placebo in each DB period. Sustained pain freedom at 2 to 24 hours postdose is defined as pain-free at 2 hours postdose, with no use of rescue medication, and no recurrence of headache pain within 2 to 24 hours postdose	2 to 24 hours postdose
Secondary	Use of Rescue Medication Postdose (DB1 and DB2)	The percentage of subjects who used rescue medication after 2 hours (2 to 24 hours) postdose compared between DFN-15 and placebo in each DB period	2 to 24 hours postdose
Secondary	Subject-Rated Treatment Satisfaction Postdose (DB1 and DB2)	Subject-rated treatment overall satisfaction was based on a 7-point scale at 2 and 4 hours postdose during each DB treatment period. The difference between the subject-rated study drug treatment satisfaction score at 2 and 4 hours postdose and the baseline PPMQ-R (Patient Perception of Migraine Questionnaire) response for the same question were summarized by treatment group (global satisfaction item at baseline asked about the subject's usual migraine treatment). The possible values of the subject treatment satisfaction scale were: 1=very satisfied, 2=satisfied, 3=somewhat satisfied, 4=neither satisfied nor dissatisfied, 5=somewhat dissatisfied, 6=dissatisfied, 7=very dissatisfied.; A decrease in values indicates improvement from baseline.	2 and 4 hours postdose
Secondary	Subject-Rated Treatment Satisfaction at 24 Hours Postdose - PPMQ-R (DB1 and DB2)	Patient Perception of Migraine Questionnaire-Revised had 30 questions assessing subject's satisfaction with migraine medication, including 3 global items & 4 subscales (i.e., efficacy, function, ease of use, tolerability). A 5-point scale (1-Not At All to 5-Extremely) was used for tolerability subscale questions; a 7-point scale (1-Very Satisfied to 7-Very Dissatisfied) was used for all other subscales and global items. Total score was average of efficacy/function/ease of use subscale scores. Each subscale & total scores were transformed to range from 0-100, with higher scores indicating better satisfaction or tolerability. Total raw score/global items were not transformed. The total raw score could range from 17 (min) to 119 (max), with lower scores indicating better satisfaction. Change from baseline scores at 24-hour-postdose for each subscale score, global item score, total score, & total raw score were summarized by treatment group below.	24 hours postdose

External Links

•   Publication of study results